170 related articles for article (PubMed ID: 34178699)
1. A Lung Adenocarcinoma Patient With a Rare
Wei Y; Cui Y; Guo Y; Li L; Zeng L
Front Oncol; 2021; 11():700345. PubMed ID: 34178699
[TBL] [Abstract][Full Text] [Related]
2. Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients.
Huang Y; Xu C; Sun Y; Wang W; Li X; Liao J; Pang L; Zeng L; Li J; Wang X; Zhang Q; Xie Z; Xiao L; Gan J; Fang W
Lung Cancer; 2022 Oct; 172():117-123. PubMed ID: 36063602
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of EGFR-Tyrosine Kinase Inhibitors for advanced non-small cell lung cancer patients harboring rare EGFR mutations of exon 18 E709X.
Hao Y; Xu M; Zhou H; Si J; Fang Y; Xu C; Song Z
Med Oncol; 2022 Dec; 40(1):34. PubMed ID: 36460861
[TBL] [Abstract][Full Text] [Related]
4. Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report.
Van Acker L; Stevens D; Vermaelen K; Surmont V
J Med Case Rep; 2021 Nov; 15(1):562. PubMed ID: 34809713
[TBL] [Abstract][Full Text] [Related]
5. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F
Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare
Zöchbauer-Müller S; Kaserer B; Prosch H; Cseh A; Solca F; Bauer MJ; Müllauer L
Front Oncol; 2020; 10():593852. PubMed ID: 33575211
[TBL] [Abstract][Full Text] [Related]
7. Lung Adenocarcinoma Patient Harboring
Zhao L; Wang Z; Du H; Chen S; Wang P
Front Oncol; 2021; 11():605853. PubMed ID: 33898306
[TBL] [Abstract][Full Text] [Related]
8.
Xu H; Yang G; Li W; Li J; Hao X; Xing P; Yang Y; Wang Y
Front Oncol; 2021; 11():713483. PubMed ID: 34540680
[TBL] [Abstract][Full Text] [Related]
9. Case report: sequential use of almonertinib based on the
Wang R; Yu S; Yu L; Zhao J; Jiao S; Wang Q; Wu Y
Transl Cancer Res; 2022 Jun; 11(6):1836-1843. PubMed ID: 35836508
[TBL] [Abstract][Full Text] [Related]
10. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
11. Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report.
Zhang Y; Shen JQ; Shao L; Chen Y; Lei L; Wang JL
World J Clin Cases; 2021 Sep; 9(27):8220-8225. PubMed ID: 34621884
[TBL] [Abstract][Full Text] [Related]
12. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
Huang YH; Hsu KH; Chin CS; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
Cancer Res Treat; 2022 Apr; 54(2):434-444. PubMed ID: 34352999
[TBL] [Abstract][Full Text] [Related]
13. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
14. Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.
Li J; Zhu L; Stebbing J; Peng L
J Cancer Res Ther; 2022 Sep; 18(5):1436-1439. PubMed ID: 36204894
[TBL] [Abstract][Full Text] [Related]
15. EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.
Shaffer W; Kobayashi IS; Sentana-Lledo D; Sundararaman S; Lee MD; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
Lung Cancer; 2023 Jul; 181():107250. PubMed ID: 37196448
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
[TBL] [Abstract][Full Text] [Related]
17. Afatinib for the treatment of metastatic non-small cell lung cancer.
Joshi M; Rizvi SM; Belani CP
Cancer Manag Res; 2015; 7():75-82. PubMed ID: 25733926
[TBL] [Abstract][Full Text] [Related]
18. Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report.
An N; Wang H; Zhu H; Yan W; Jing W; Kong L; Zhang Y; Yu J
Onco Targets Ther; 2019; 12():7399-7404. PubMed ID: 31686847
[TBL] [Abstract][Full Text] [Related]
19. Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report.
Wu L; Fang C; Zhao W; Li D; Tang S; Li X; Ji M
Ann Transl Med; 2022 Jan; 10(2):116. PubMed ID: 35282062
[TBL] [Abstract][Full Text] [Related]
20. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.
Zhang Y; Sheng J; Kang S; Fang W; Yan Y; Hu Z; Hong S; Wu X; Qin T; Liang W; Zhang L
PLoS One; 2014; 9(9):e107161. PubMed ID: 25222496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]